Which has higher earnings & valuation, MEDP or EHC?

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.43 $451.12M $17.06 34.19 Encompass Health $6.21B 1.93 $566.20M $6.14 19.77

Does the media favor MEDP or EHC?

In the previous week, Medpace had 3 more articles in the media than Encompass Health. MarketBeat recorded 11 mentions for Medpace and 8 mentions for Encompass Health. Medpace's average media sentiment score of 1.38 beat Encompass Health's score of 0.97 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Encompass Health 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ELV or MEDP?

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elevance Health $199.13B 0.44 $5.66B $22.50 17.76 Medpace $2.53B 6.43 $451.12M $17.06 34.19

Is ELV or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Elevance Health's net margin of 2.47%. Medpace's return on equity of 110.15% beat Elevance Health's return on equity. Company Net Margins Return on Equity Return on Assets Elevance Health 2.47% 14.64% 5.22% Medpace 17.67% 110.15% 24.84%

Does the media refer more to ELV or MEDP?

In the previous week, Elevance Health had 11 more articles in the media than Medpace. MarketBeat recorded 22 mentions for Elevance Health and 11 mentions for Medpace. Elevance Health's average media sentiment score of 1.47 beat Medpace's score of 1.38 indicating that Elevance Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elevance Health 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MEDP or HIMS?

In the previous week, Hims & Hers Health had 33 more articles in the media than Medpace. MarketBeat recorded 44 mentions for Hims & Hers Health and 11 mentions for Medpace. Medpace's average media sentiment score of 1.38 beat Hims & Hers Health's score of 0.09 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 6 Very Positive mention(s) 4 Positive mention(s) 29 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, MEDP or IQV?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.43 $451.12M $17.06 34.19 IQVIA $16.98B 2.49 $1.36B $8.06 31.92

Is MEDP or IQV more profitable?

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% IQVIA 8.10% 30.25% 6.54%

Does the media prefer MEDP or IQV?

In the previous week, IQVIA had 10 more articles in the media than Medpace. MarketBeat recorded 21 mentions for IQVIA and 11 mentions for Medpace. Medpace's average media sentiment score of 1.38 beat IQVIA's score of 1.26 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 16 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer A or MEDP?

In the previous week, Agilent Technologies had 6 more articles in the media than Medpace. MarketBeat recorded 17 mentions for Agilent Technologies and 11 mentions for Medpace. Medpace's average media sentiment score of 1.38 beat Agilent Technologies' score of 0.73 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medpace (MEDP) Competitors

$583.22 -7.67 (-1.30%)

As of 03:15 PM Eastern

Compare

MEDP vs. EHC, ELV, HIMS, IQV, and A

Should you buy Medpace stock or one of its competitors? Medpace's main competitors and comparable companies include Encompass Health (EHC), Elevance Health (ELV), Hims & Hers Health (HIMS), IQVIA (IQV), and Agilent Technologies (A). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Medpace compare to Encompass Health?

Medpace (NASDAQ:MEDP) and Encompass Health (NYSE:EHC) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Medpace currently has a consensus target price of $595.20, indicating a potential upside of 2.05%. Encompass Health has a consensus target price of $148.71, indicating a potential upside of 22.53%. Given Encompass Health's stronger consensus rating and higher possible upside, analysts plainly believe Encompass Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Medpace has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Encompass Health has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Medpace has a net margin of 17.67% compared to Encompass Health's net margin of 10.01%. Medpace's return on equity of 110.15% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Encompass Health	10.01%	18.08%	8.22%

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.43	$451.12M	$17.06	34.19
Encompass Health	$6.21B	1.93	$566.20M	$6.14	19.77

In the previous week, Medpace had 3 more articles in the media than Encompass Health. MarketBeat recorded 11 mentions for Medpace and 8 mentions for Encompass Health. Medpace's average media sentiment score of 1.38 beat Encompass Health's score of 0.97 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Encompass Health	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

78.0% of Medpace shares are owned by institutional investors. Comparatively, 97.3% of Encompass Health shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 1.8% of Encompass Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Medpace beats Encompass Health on 10 of the 17 factors compared between the two stocks.

How does Medpace compare to Elevance Health?

Elevance Health (NYSE:ELV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevance Health	$199.13B	0.44	$5.66B	$22.50	17.76
Medpace	$2.53B	6.43	$451.12M	$17.06	34.19

Elevance Health has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

89.2% of Elevance Health shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.3% of Elevance Health shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Elevance Health presently has a consensus target price of $440.90, indicating a potential upside of 10.32%. Medpace has a consensus target price of $595.20, indicating a potential upside of 2.05%. Given Elevance Health's stronger consensus rating and higher probable upside, analysts clearly believe Elevance Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevance Health	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Elevance Health had 11 more articles in the media than Medpace. MarketBeat recorded 22 mentions for Elevance Health and 11 mentions for Medpace. Elevance Health's average media sentiment score of 1.47 beat Medpace's score of 1.38 indicating that Elevance Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elevance Health	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.67% compared to Elevance Health's net margin of 2.47%. Medpace's return on equity of 110.15% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elevance Health	2.47%	14.64%	5.22%
Medpace	17.67%	110.15%	24.84%

Summary

Elevance Health beats Medpace on 9 of the 16 factors compared between the two stocks.

How does Medpace compare to Hims & Hers Health?

Medpace (NASDAQ:MEDP) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

In the previous week, Hims & Hers Health had 33 more articles in the media than Medpace. MarketBeat recorded 44 mentions for Hims & Hers Health and 11 mentions for Medpace. Medpace's average media sentiment score of 1.38 beat Hims & Hers Health's score of 0.09 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	6 Very Positive mention(s)	4 Positive mention(s)	29 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Medpace has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.42, meaning that its share price is 142% more volatile than the broader market.

78.0% of Medpace shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medpace has higher earnings, but lower revenue than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.43	$451.12M	$17.06	34.19
Hims & Hers Health	$2.58B	2.51	$128.37M	-$0.63	N/A

Medpace presently has a consensus target price of $595.20, suggesting a potential upside of 2.05%. Hims & Hers Health has a consensus target price of $32.50, suggesting a potential upside of 17.13%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Medpace has a net margin of 17.67% compared to Hims & Hers Health's net margin of -5.51%. Medpace's return on equity of 110.15% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

Summary

Medpace beats Hims & Hers Health on 11 of the 16 factors compared between the two stocks.

How does Medpace compare to IQVIA?

Medpace (NASDAQ:MEDP) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

78.0% of Medpace shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, IQVIA had 10 more articles in the media than Medpace. MarketBeat recorded 21 mentions for IQVIA and 11 mentions for Medpace. Medpace's average media sentiment score of 1.38 beat IQVIA's score of 1.26 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	16 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.43	$451.12M	$17.06	34.19
IQVIA	$16.98B	2.49	$1.36B	$8.06	31.92

Medpace presently has a consensus price target of $595.20, indicating a potential upside of 2.05%. IQVIA has a consensus price target of $243.63, indicating a potential downside of 5.29%. Given Medpace's higher possible upside, research analysts clearly believe Medpace is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
IQVIA	8.10%	30.25%	6.54%

Summary

Medpace beats IQVIA on 9 of the 17 factors compared between the two stocks.

How does Medpace compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Agilent Technologies has higher revenue and earnings than Medpace. Agilent Technologies is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$7.37B	5.56	$1.30B	$5.08	28.59
Medpace	$2.53B	6.43	$451.12M	$17.06	34.19

Agilent Technologies currently has a consensus target price of $170.33, suggesting a potential upside of 17.26%. Medpace has a consensus target price of $595.20, suggesting a potential upside of 2.05%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Agilent Technologies is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.80
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Agilent Technologies had 6 more articles in the media than Medpace. MarketBeat recorded 17 mentions for Agilent Technologies and 11 mentions for Medpace. Medpace's average media sentiment score of 1.38 beat Agilent Technologies' score of 0.73 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Agilent Technologies has a net margin of 19.53% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.53%	24.45%	13.09%
Medpace	17.67%	110.15%	24.84%

87.4% of Agilent Technologies shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.2% of Agilent Technologies shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Agilent Technologies beats Medpace on 10 of the 17 factors compared between the two stocks.

Get Medpace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MEDP vs. The Competition

Export

Metric	Medpace	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.23B	$9.74B	$7.13B	$12.80B
Dividend Yield	N/A	1.47%	2.54%	9.15%
P/E Ratio	34.09	65.53	272.43	25.24
Price / Sales	6.43	299.16	696.72	107.75
Price / Cash	34.75	26.85	77.07	52.39
Price / Book	35.78	5.26	10.78	6.33
Net Income	$451.12M	$56.67B	$3.48B	$357.86M
7 Day Performance	-1.65%	-2.65%	-1.09%	-0.12%
1 Month Performance	-1.26%	0.20%	2.51%	-1.01%
1 Year Performance	20.11%	24.00%	21.14%	11.72%

Medpace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MEDP Medpace	3.3677 of 5 stars	$583.22 -1.3%	$595.20 +2.1%	+20.1%	$16.23B	$2.53B	34.09	6,200	Positive News
EHC Encompass Health	4.8996 of 5 stars	$120.51 -0.3%	$148.71 +23.4%	-4.3%	$11.92B	$5.94B	19.63	42,000
ELV Elevance Health	4.6443 of 5 stars	$392.81 -0.4%	$440.90 +12.2%	+30.5%	$85.54B	$199.13B	17.46	97,100	Positive News
HIMS Hims & Hers Health	2.499 of 5 stars	$29.56 +2.5%	$32.50 +9.9%	-43.6%	$6.73B	$2.35B	N/A	2,442	Trending News
IQV IQVIA	3.6655 of 5 stars	$261.29 -0.2%	$241.88 -7.4%	+38.2%	$43.08B	$16.31B	32.42	93,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MEDP) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and A

How does Medpace compare to Encompass Health?

Summary

How does Medpace compare to Elevance Health?

Summary

How does Medpace compare to Hims & Hers Health?

Summary

How does Medpace compare to IQVIA?

Summary

How does Medpace compare to Agilent Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and A

How does Medpace compare to Encompass Health?

Do analysts rate MEDP or EHC?

Which has more volatility & risk, MEDP or EHC?

Is MEDP or EHC more profitable?

Which has higher earnings & valuation, MEDP or EHC?

Does the media favor MEDP or EHC?

Do institutionals and insiders believe in MEDP or EHC?

Summary

How does Medpace compare to Elevance Health?

Which has higher earnings and valuation, ELV or MEDP?

Which has more volatility & risk, ELV or MEDP?

Do insiders and institutionals hold more shares of ELV or MEDP?

Do analysts prefer ELV or MEDP?

Does the media refer more to ELV or MEDP?

Is ELV or MEDP more profitable?

Summary

How does Medpace compare to Hims & Hers Health?

Does the media refer more to MEDP or HIMS?

Which has more volatility and risk, MEDP or HIMS?

Do institutionals and insiders believe in MEDP or HIMS?

Which has preferable earnings and valuation, MEDP or HIMS?

Do analysts rate MEDP or HIMS?

Is MEDP or HIMS more profitable?

Summary

How does Medpace compare to IQVIA?

Do institutionals & insiders have more ownership in MEDP or IQV?

Does the media prefer MEDP or IQV?

Which has higher valuation & earnings, MEDP or IQV?

Do analysts rate MEDP or IQV?

Which has more volatility and risk, MEDP or IQV?

Is MEDP or IQV more profitable?

Summary

How does Medpace compare to Agilent Technologies?

Which has better valuation & earnings, A or MEDP?

Do analysts prefer A or MEDP?

Does the media prefer A or MEDP?

Which has more risk and volatility, A or MEDP?

Is A or MEDP more profitable?

Do institutionals and insiders hold more shares of A or MEDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools